[DEBUG-WINDOW 처리영역 보기]
즐겨찾기  |  뉴스레터  |  오늘의 정보  |  e브릭몰e브릭몰 회원가입   로그인
BRIC홈 한국을 빛내는 사람들
제품평가단 모집
스폰서배너광고 안내  배너1 배너2 배너3
LABox-과학으로 본 코로나19 (COVID-19)
전체보기 추천논문 상위피인용논문 인터뷰 그이후 한빛사통계
이슬기
이슬기 (Seulki Lee) 저자 이메일 보기
Johns Hopkins School of Medicine
저자CV 보기
93 KB
 
조회 1124  인쇄하기 주소복사 트위터 공유 페이스북 공유 
Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells
Yumin Oh1,2,10, Ogyi Park1,2,3,10, Magdalena Swierczewska1,2,10, James P. Hamilton,4 Jong-Sung Park1,2, Tae Hyung Kim1,2, Sung-Mook Lim5, Hana Eom5, Dong Gyu Jo5, Choong-Eun Lee6, Raouf Kechrid3, Panagiotis Mastorakos2, Clark Zhang2, Sei Kwang Hahn7, Ok-Cheol Jeon8, Youngro Byun8, Kwangmeyung Kim9, Justin Hanes2, Kang Choon Lee5, Martin G. Pomper1, Bin Gao3,* and Seulki Lee1,2,*

1The Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 2The Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 3Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA 4Divison of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 5College of Pharmacy, Sungkyunkwan University, Suwon, Korea 6Department of Biological Science, Sungkyunkwan University, Suwon, Korea 7Department of Materials Science and Engineering, Pohang University of Science and Technology, Pohang, Korea 8College of Pharmacy, Seoul National University, Seoul, Korea 9Center for Theragnosis, Korea Institute of Science and Technology, Seoul, Korea 10These authors contributed equally to this work.

* Correspondence authors: Bin Gao, M.D., Ph.D., Laboratory of Liver Diseases, NIAAA/NIH, 5625 Fishers Lane, Bethesda, MD 20892. and Seulki Lee, Ph.D. The Russell H. Morgan Department of Radiology and Radiological Sciences, The Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University, School of Medicine, Baltimore, MD 21231. 

Abstract
Liver fibrosis is a common outcome of chronic liver disease and leads to liver cirrhosis and hepatocellular carcinoma. No FDA-approved targeted anti-fibrotic therapy exists. Activated hepatic stellate cells (aHSCs) are the major cell types responsible for liver fibrosis; therefore, eradication of aHSCs, while preserving quiescent HSCs and other normal cells, is a logical strategy to stop and/or reverse liver fibrogenesis/fibrosis. However, there are no effective approaches to specifically deplete aHSCs during fibrosis without systemic toxicity. aHSCs are associated with elevated expression of death receptors (DRs) and become sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell death. Treatment with recombinant TRAIL could be a potential strategy to ameliorate liver fibrosis; however, the therapeutic application of recombinant TRAIL is halted due to its very short half-life. To overcome this problem, we previously generated PEGylated TRAIL (TRAILPEG) that has a much longer half-life in rodents than native-type TRAIL. Here, we demonstrate that intravenous TRAILPEG has a markedly extended half-life over native-type TRAIL in non-human primates and has no toxicity in primary human hepatocytes. Intravenous injection of TRAILPEG directly induces apoptosis of aHSCs in vivo and ameliorates carbon tetrachloride-induced fibrosis/cirrhosis in rats by simultaneously down-regulating multiple key fibrotic markers that are associated with aHSCs. In conclusion, TRAIL-based therapies could serve as new therapeutics for liver fibrosis/cirrhosis and possibly other fibrotic diseases. This article is protected by copyright. All rights reserved.

Keywords: apoptosis, cirrhosis, death receptors, fibrosis, hepatic stellate cells, TRAIL
논문정보
- 형식: Research article
- 게재일: 2015년 12월 (BRIC 등록일 2015-12-29)
- 연구진: 국내+국외 연구진
- 분야: Medicine
세포 형광 이미징 멀티플렉싱을 위한 초고속 사이클링[Angew. Chem.-Int. Edit.]
고진아
발표: 고진아 (Massachusetts General Ho...)
일자: 2020년 4월 14일 (화) 오전 10시 (한국시간)
언어: 영어
참석자 접수신청하기

  댓글 0
등록
 
목록
오송첨단의료산업진흥재단
관련링크
이슬기 님 전체논문보기 >
관련인물
감태인 (존스홉킨스 의과대학)
고한석 (Johns Hopkins U...)
김광명 (한국과학기술연구원(KIST)...)
김태형 (Johns Hopkins U...)
류주희 (한국과학기술연구원)
박옥이 (NIAAA/NIH)
박재형 (성균관대학교)
박종성 (D&D Pharmatech/...)
안철희 (서울대학교)
오유민 (Johns Hopkins U...)
윤승필 (Johns Hopkins U...)
이강춘 (성균관대학교)
차의준 (서울대학교)
최기영 (한국과학기술연구원)
관련분야 논문보기
Medicine

외부링크
Google (by Seulki Lee)
Pubmed (by Seulki Lee)
제품평가
[필코리아테크놀로지]
Sapphire Biomolecular Imager
제품이미지
모집인원: 10명
모집기간: ~3/31
신청조건: BRIC 회원
평가자 혜택

- 참가자 전원 10만원 상품권 제공
- 우수평가자 5명에게 10만원 상품권 추가 제공

제품평가자 모집중
프리미엄 Bio일정 Bio일정 프리미엄 안내
[재직자무료교육] 분석기기(HPLC) 활용 품질검사 실습(4.9~4.10) / 화장품 제형제조 기술 실습(4.13~4.14)
[재직자무료교육] 분석기기(HPLC) 활용 품질검사 실습(4.9~4.10) / 화장품 제형제조 기술 실습(4.13~4.14)
날짜: 2020.04.09~14
장소: 충청북도 청주시 흥덕구 오송읍 오송생명1로 194-41 충북산학융합본부 기업연구1관 교육장
[BRIC Webinar]새로운 염기서열 분석방법(BTSeq)을 이용한 hCoV-19 전장유전체 염기서열의 동정 [CELEMICS]
[BRIC Webinar]Infectious disease 연구에 Chromium single cell solution을 활용한 사례[다온비에스]
위로가기
한빛사 홈  |  한빛사FAQ  |  한빛사 문의 및 제안
 |  BRIC소개  |  이용안내  |  이용약관  |  개인정보처리방침  |  이메일무단수집거부
Copyright © BRIC. All rights reserved.  |  문의 member@ibric.org
트위터 트위터    페이스북 페이스북   유튜브 유튜브    RSS서비스 RSS
에펜도르프코리아